Source: Google NewsPublished on 2022-06-21
Related Articles:
- The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s. It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
- The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
- The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
- Monthly Research Review – December 2021 December 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
- Monthly Research Review – October 2021 October 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during October 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
- Monthly Research Review – December 2020 December 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- Mo better for TEVA with Modag? October 27, 2021 # # # # This week the pharmaceutical company TEVA Pharmaceuticals Industries Ltd has announced a deal with a small German biotech firm called MODAG. The two companies are forming a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b. Anle138b is a small molecule inhibitor of the believed to be toxic forms of…
- ADepTing to the UCB-Novartis deal December 6, 2021 # # # # Alpha synuclein has long been viewed at “Public enemy #1” by the Parkinson’s research community. This sticky, abundant protein starts to cluster (or aggregate) in Parkinson’s. There have been several attempts to reduce levels of the protein floating around outside of cells (using “immunotherapy” approaches) But now clinical research is ramping up to determine if reducing…
- Monthly Research Review – June 2021 June 30, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during June 2021. The post is divided into 10 parts based on the type of research: Top 4 pieces of Parkinson’s news Articles of general interest Basic biology…
- 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
- Global Parkinson's Disease Treatments Market 2019-2026 | Top key players are GSK ,Merck ,Novartis ,Teva ,Boehringer Ingelheim ,Impax ,Abbvie ,Valeant Pharmaceuticals ,Lundbeck ,Sun Pharma ,Wockhardt ,Acadia ,UCB - Financial Newspaper September 5, 2019 Global Parkinson's Disease Treatments Market 2019-2026 | Top key players are GSK ,Merck ,Novartis ,Teva ,Boehringer Ingelheim ,Impax ,Abbvie ,Valeant Pharmaceuticals ,Lundbeck ,Sun Pharma ,Wockhardt ,Acadia ,UCB Financial NewspaperGlobal Parkinson's Disease Treatments Market Professional Survey Report 2019. Parkinson's Disease Treatments Market 2019 Global Industry research report ...
- Parkinson's Disease Treatment Market Size, Share, Development by 2025 Top Key players like Teva, Novartis AG, GSK, AbbVie , Merck , Boehringer Ingelheim, Impax Laboratories , Lundbeck, UCB, Valeant Pharmaceuticals, Acadia , Sun Pharma,… August 5, 2019 Parkinson's Disease Treatment Market Size, Share, Development by 2025 Top Key players like Teva, Novartis AG, GSK, AbbVie , Merck , Boehringer Ingelheim, Impax Laboratories , Lundbeck, UCB, Valeant Pharmaceuticals, Acadia , Sun Pharma, Wockhardt Market Report GazetteMarket Report Gazette provides latest industry trending news, news *service*, IT & Technology news helps businesses connect with their target audiences in ...
- Parkinson’s Disease Treatment Market Size, Scope and Forecast | GSK, Merck, Novartis, Teva, BoehringerIngelheim, Impax, Abbvie, Valeant Pharmaceuticals, Lundbeck, Sun Pharma - Designer Women June 14, 2022 Parkinson’s Disease Treatment Market Size, Scope and Forecast | GSK, Merck, Novartis, Teva, BoehringerIngelheim, Impax, Abbvie, Valeant Pharmaceuticals, Lundbeck, Sun Pharma Designer Women
- Parkinson's Disease Treatment Market Size and Growth 2021-2028 | Top Vendors – GSK , Merck , Novartis , Teva, BoehringerIngelheim, Impax, Abbvie, Valeant Pharmaceuticals – The Courier - The Courier June 7, 2021 Parkinson's Disease Treatment Market Size and Growth 2021-2028 | Top Vendors – GSK , Merck , Novartis , Teva, BoehringerIngelheim, Impax, Abbvie, Valeant Pharmaceuticals – The Courier The Courier
- Year in review: 2021 December 31, 2021 # # # # As with the preceding year, 2021 proved to be challenging due to the continuing COVID-19 pandemic (and it is not over yet). Vaccines were rolled out with remarkable speed, but equally new variants of the virus popped up and have kept Governments and health regulatory bodies on their toes. An amazing feature of the last two…
- Parkinson's Disease Treatment Market Size, Scope and Forecast | GSK, Merck, Novartis, Teva, BoehringerIngelheim, Impax, Abbvie, Valeant Pharmaceuticals, Lundbeck, Sun Pharma – ManufactureLink - ManufactureLink May 30, 2022 Parkinson's Disease Treatment Market Size, Scope and Forecast | GSK, Merck, Novartis, Teva, BoehringerIngelheim, Impax, Abbvie, Valeant Pharmaceuticals, Lundbeck, Sun Pharma – ManufactureLink ManufactureLink
- Parkinson's Disease Treatment Market Size, Scope and Forecast | GSK, Merck, Novartis, Teva, BoehringerIngelheim, Impax, Abbvie, Valeant Pharmaceuticals, Lundbeck, Sun Pharma – The Greater Binghamton Business Journal - The Greater Binghamton… June 2, 2022 Parkinson's Disease Treatment Market Size, Scope and Forecast | GSK, Merck, Novartis, Teva, BoehringerIngelheim, Impax, Abbvie, Valeant Pharmaceuticals, Lundbeck, Sun Pharma – The Greater Binghamton Business Journal The Greater Binghamton Business Journal
- Parkinson’s: Here Comes the Sun March 22, 2022 “The sun shines on everybody. You’ve got to keep believing.” Dontrelle Willis “After the rain, the sun will reappear. There is life. After the pain, the joy will still be here.” Walt Disney Introduction: Recently, I have written several blog posts focused on musical songs that deal with perseverance. And the focus was to use the music/lyrics to live better…
- Parkinson's Disease Treatment Market Size, Trends and Forecast to 2029 | GSK, Merck, Novartis, Teva, BoehringerIngelheim, Impax, Abbvie, Valeant Pharmaceuticals, Lundbeck, Sun Pharma – Carbon Valley Farmer and Miner - Carbon Valley Farmer and Miner May 25, 2022 Parkinson's Disease Treatment Market Size, Trends and Forecast to 2029 | GSK, Merck, Novartis, Teva, BoehringerIngelheim, Impax, Abbvie, Valeant Pharmaceuticals, Lundbeck, Sun Pharma – Carbon Valley Farmer and Miner Carbon Valley Farmer and Miner
- Global Parkinson's Disease Treatments Market 2019 – GSK, Merck, Novartis, Teva, Boehringer Ingelheim, Impax, Abbvie, Valeant Pharmaceuticals, Lundbeck - Industry News Hour November 5, 2019 Global Parkinson's Disease Treatments Market 2019 – GSK, Merck, Novartis, Teva, Boehringer Ingelheim, Impax, Abbvie, Valeant Pharmaceuticals, Lundbeck Industry News Hour
- Monthly Research Review – August 2021 August 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during August 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
- Monthly research review – April 2021 April 30, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during April 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…